Abstract | PURPOSE: METHODS: RESULTS: From our search of electronic databases, we identified and screened 4,561 unique records. We judged 60 articles to have reported findings for cohorts of patients who met our inclusion criteria, (12 arms of randomized clinical trials, 11 prospective cohort studies, and 37 retrospective cohort studies), which included 244 cases of endophthalmitis and 639,391 intravitreal injections of anti- vascular endothelial growth factor agents. The final pooled estimate endophthalmitis proportions were 9/10,000 (95% confidence interval, 7/10,000-12/10,000) in the antibiotic-treated group and 3/10,000 (95% confidence interval, 2/10,000-5/10,000) in the untreated group. The estimated incidence of endophthalmitis with topical antibiotic prophylaxis was approximated three times the incidence without prophylaxis. Random effects regression showed that none of the study characteristics significantly affected the effect size in either group. CONCLUSION:
|
Authors | Michele Reibaldi, Alfredo Pulvirenti, Teresio Avitabile, Vincenza Bonfiglio, Andrea Russo, Cesare Mariotti, Claudio Bucolo, Rodolfo Mastropasqua, Guglielmo Parisi, Antonio Longo |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 38
Issue 1
Pg. 1-11
(Jan 2018)
ISSN: 1539-2864 [Electronic] United States |
PMID | 28267115
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Anti-Bacterial Agents
- Vascular Endothelial Growth Factor A
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage)
- Anti-Bacterial Agents
(therapeutic use)
- Antibiotic Prophylaxis
- Endophthalmitis
(epidemiology, etiology)
- Eye Infections, Bacterial
(epidemiology, etiology)
- Global Health
- Humans
- Intravitreal Injections
(adverse effects)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
|